Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vusolimogene oderparepvec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vusolimogene oderparepvec overview
RP-1 is under development for the treatment of advanced or metastatic cutaneous squamous cell carcinoma, angiosarcoma, mixed advanced solid tumors including urothelial cell carcinoma, metastatic breast cancer, metastatic uveal melanoma, ocular melanoma, metastatic bladder cancer, non-small cell lung cancer, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, triple negative breast cancer and microsatellite instability high cancers including colorectal and esophageal cancers. RP-1 is used to deliver certain optimized immune activating proteins directly into the immune response-initiating tumor and to draining lymph nodes. The drug candidate is a replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. It is developed based on Immulytic platform. It is administered through intratumor route.
It was under development for the treatment of soft tissue sarcoma.
Replimune overview
Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co-stimulatory ligands. Its Immulytic platform is designed to maximize systemic immune activation in tumor neoantigens, through viral-mediated immunogenic tumor cell killing and deliver optimal combinations of immune-activating proteins into a tumor and draining lymph nodes. Replimune is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of Vusolimogene oderparepvec’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
